YOUR BUSINESS AUTHORITY

Springfield, MO

Log in Subscribe

AstraZeneca buys majority stake of Acerta for $4B

Posted online
AstraZeneca announced today it agreed to buy a 55 percent stake in privately held biotech firm Acerta Pharma for $4 billion.

Under the terms of the deal, AstraZeneca will pay $2.5 billion up front, with the remaining $1.5 billion to be paid on receipt of the first regulatory approval for the medicine Acalabrutinib or the end of 2018, whichever comes first.

Acalabrutinib could sell as much as $5 billion a year. The drug is designed to fight relapsed chronic lymphocytic leukemia.

Read more from Reuters.

Comments

No comments on this story |
Please log in to add your comment
Editors' Pick
Letter to the Editor: No half-baked cake for our kids. No half-baked school grades, either.

Nixa Superintendent Gearl Loden weighs in on A-F grade cards.

Most Read
Update cookies preferences